Degarelix

Generic Name: Degarelix

Brand Names: Firmagon, Degarelix Accord

Drug Type: Small Molecule

Chemical Formula: C_₈₂H_₁₀₃ClN_₁₈O_₁₆

CAS Number: 214766-78-6

Unique Ingredient Identifier: SX0XJI3A11

Background: Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.

Indication: Degaralix is used for the management of advanced prostate cancer.

Associated Conditions: Advanced Prostate Cancer

Clinical Trials

Degarelix Neo-Adjuvant Radical Prostatectomy Trial

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Degarelix
Drug: Casodex
Drug: LHRH Agonist

First Posted Date: 2012-08-28

Last Posted Date: 2015-12-22

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 35

Registration Number: NCT01674270

Locations: 🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada
🇨🇦
University Health Network, Toronto, Ontario, Canada

Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)

Phase 2

Conditions: Prostate Neoplasm

Interventions: Drug: Degarelix

First Posted Date: 2012-06-28

Last Posted Date: 2012-06-28

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 40

Registration Number: NCT01630967

Locations: 🇨🇦
British Columbia Cancer Agency, Vancouver, British Columbia, Canada

A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer

Phase 2

Terminated

Conditions: Prostatic Neoplasms

Interventions: Drug: Degarelix

First Posted Date: 2012-03-07

Last Posted Date: 2020-05-07

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 5

Registration Number: NCT01545882

Locations: 🇨🇦
Princess Margeret Hospital, Toronto, Ontario, Canada
🇨🇦
London Regional Cancer Centre, London, Ontario, Canada
🇨🇦
Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada

Androgen Deprivation Therapy Prior to Prostatectomy for Patients with Intermediate and High Risk Prostate Cancer

Not Applicable

Completed

Conditions: Prostatic Adenocarcinoma
Prostate Cancer

Interventions: Drug: degarelix injection
Drug: androgen deprivation therapy

First Posted Date: 2012-03-01

Last Posted Date: 2024-10-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 41

Registration Number: NCT01542021

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Firmagon (Degarelix) Intermittent Therapy

Phase 4

Terminated

Conditions: Prostate Cancer Recurrent

Interventions: Drug: degarelix

First Posted Date: 2012-01-19

Last Posted Date: 2019-09-23

Lead Sponsor: Canadian Urology Research Consortium

Target Recruit Count: 144

Registration Number: NCT01512472

Locations: 🇨🇦
Ultra-Med Research, Pointe Claire, Quebec, Canada
🇨🇦
The Prostate Centre, Vancouver, British Columbia, Canada
🇨🇦
Centre of Clinical Research, Halifax, Nova Scotia, Canada

and more 12 locations

Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Degarelix

First Posted Date: 2011-12-14

Last Posted Date: 2013-12-12

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 76

Registration Number: NCT01491971

Locations: 🇺🇸
South Orange County Urology Research, Laguna Hills, California, United States
🇨🇦
Bramalea Medical Centre, Brampton, Ontario, Canada
🇺🇸
South Florida Medical Research, Aventura, Florida, United States

and more 12 locations

Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Degarelix

First Posted Date: 2011-10-05

Last Posted Date: 2020-01-27

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 50

Registration Number: NCT01446991

Locations: 🇨🇦
Abbottsford Cancer Center, Abbottsford, British Columbia, Canada
🇨🇦
Fraser Valley Cancer Center, Surrey, British Columbia, Canada
🇨🇦
Vancouver Cancer Center, Vancouver, British Columbia, Canada